Last reviewed · How we verify

PGL4001 — Competitive Intelligence Brief

PGL4001 (PGL4001) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective progesterone receptor modulator (SPRM). Area: Gynecology / Women's Health.

phase 3 Selective progesterone receptor modulator (SPRM) Progesterone receptor (PR) Gynecology / Women's Health Small molecule Live · refreshed every 30 min

Target snapshot

PGL4001 (PGL4001) — PregLem SA. PGL4001 is a selective progesterone receptor modulator that acts as a progesterone agonist to reduce uterine contractions and bleeding.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PGL4001 TARGET PGL4001 PregLem SA phase 3 Selective progesterone receptor modulator (SPRM) Progesterone receptor (PR)
OBE2109 OBE2109 ObsEva SA phase 3 Selective progesterone receptor modulator (SPRM) Progesterone receptor (PR)
SH D 593 B (Miranova) SH D 593 B (Miranova) Bayer phase 3 Selective progesterone receptor modulator (SPRM) Progesterone receptor (PR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective progesterone receptor modulator (SPRM) class)

  1. Bayer · 1 drug in this class
  2. ObsEva SA · 1 drug in this class
  3. PregLem SA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PGL4001 — Competitive Intelligence Brief. https://druglandscape.com/ci/pgl4001. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: